Sen. Richard Blumenthal Sells Shares of Oncology Institute, Inc. (NASDAQ:STLN)

Key Points

• Sen. Richard Blumenthal sold multiple Oncology Institute shares in September, with disclosed transaction values ranging from $1,001 to $50,000.
• Oncology Institute shares opened at $6.29, with a market capitalization of about $621.7 million; its latest quarterly revenue of $161.28 million exceeded analyst expectations, though it reported a loss of $0.08 per share.
• Analyst sentiment remains broadly positive, with four Buy ratings and one Sell rating, a consensus “Moderate Buy” rating, and an average price target of $9.00.

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. NASDAQ: STLN. In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 18th.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Oncology Institute NASDAQ: STLN on 9/23/2026.
• Sold $15,001 - $50,000 in shares of Oncology Institute NASDAQ: STLN on 9/22/2026.
• Sold $1,001 - $15,000 in shares of Oncology Institute NASDAQ: STLN on 9/22/2026.
• Sold $15,001 - $50,000 in shares of Oncology Institute NASDAQ: STLN on 9/18/2026.

Oncology Institute Stock Performance

Shares of NASDAQ:STLN opened at $6.29 on Tuesday. The business has a 50 day moving average price of $6.46. The company has a market capitalization of $621.70 million, a PE ratio of -20.97 and a beta of 0.39. Oncology Institute, Inc. has a 52-week low of $2.32 and a 52-week high of $7.13.

Oncology Institute (NASDAQ:STLN - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $161.28 million during the quarter, compared to analyst estimates of $152.80 million. As a group, sell-side analysts anticipate that Oncology Institute, Inc. will post -0.21 EPS for the current fiscal year.

Insider Activity

In other Oncology Institute news, Director Brad Hively sold 298,853 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the completion of the transaction, the director directly owned 411,976 shares of the company's stock, valued at approximately $2,681,963.76. This trade represents a 42.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 12,000 shares of Oncology Institute stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $6.54 per share, with a total value of $78,480.00. Following the completion of the transaction, the insider owned 10,660,858 shares of the company's stock, valued at $69,722,011.32. This represents a 0.11% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 4.40% of the company's stock.

Institutional Trading of Oncology Institute

Several large investors have recently bought and sold shares of STLN. BlackRock Inc. acquired a new position in shares of Oncology Institute in the 2nd quarter valued at $25,787,000. State Street Corp purchased a new stake in Oncology Institute during the 2nd quarter valued at about $8,432,000. Renaissance Technologies LLC increased its holdings in shares of Oncology Institute by 25.1% in the first quarter. Renaissance Technologies LLC now owns 902,809 shares of the company's stock valued at $2,772,000 after purchasing an additional 180,909 shares during the period. Manatuck Hill Partners LLC acquired a new position in shares of Oncology Institute in the second quarter valued at about $2,444,000. Finally, Walleye Capital LLC acquired a new position in shares of Oncology Institute in the second quarter valued at about $2,421,000. Hedge funds and other institutional investors own 36.86% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Needham & Company LLC upped their target price on Oncology Institute from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, October 14th. Lake Street Capital initiated coverage on Oncology Institute in a research note on Monday, July 6th. They set a "buy" rating and a $10.00 price objective for the company. Weiss Ratings began coverage on Oncology Institute in a research report on Thursday, August 6th. They set a "sell (d-)" rating on the stock. Finally, BTIG Research lifted their target price on Oncology Institute from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.